Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GDUFA: Fee Avoidance Affects Rates Again

Executive Summary

Industry avoided application supplement fees by using CBE submissions instead, forcing FDA to change its estimates and sending generic drug user fees higher.


Related Content

Generic User Fee Hikes Could Disrupt US FDA Drug Pricing Campaign
Generic User Fee 'Relief' For Small Firms Would Mean Bigger Bills For Large One
Drug Review Personnel Costs Dropping, Remain “Completely Normal,” FDA Says
FDA User Fees In FY 2014: Burden Per Application Grows As Submission Projections Fall
Generic User Fees Need Small Business Waiver, Firms Say; Congress May Agree
GDUFA Launch Pains: Facility List Fluctuations, Back-Due Backlog Fees
GDUFA Self-Identification Woes Can’t Deflate Industry, FDA Enthusiasm
Backlog Backfire: FDA Sees Increase In Pending Generic Applications At Deadline
ANDA Sponsors May Need Extra Three Months To Avoid DMF-Related Delays
Generic User Fee Agreement Includes FDA Pledge To Determine Best Use Of Foreign Regulator Inspections





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts